1. Metabolic Enzyme/Protease
  2. Isocitrate Dehydrogenase (IDH)

Isocitrate Dehydrogenase (IDH)

Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producingalpha-ketoglutarate (α-ketoglutarate) and CO2. This is a two-step process, which involves oxidation of isocitrate (a secondary alcohol) to oxalosuccinate(a ketone), followed by the decarboxylation of the carboxyl group beta to the ketone, forming alpha-ketoglutarate. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as themitochondrion and peroxisome.

Isocitrate Dehydrogenase (IDH) Related Products (13):

Cat. No. Product Name Effect Purity
  • HY-18767
    Ivosidenib Inhibitor 99.05%
    Ivosidenib is a inhibitor of IDH1.
  • HY-18690
    Enasidenib Inhibitor 99.95%
    Enasidenib is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
  • HY-18082
    AGI-5198 Inhibitor 99.99%
    AGI-5198 is a novel R132H-IDH1 inhibitor, used for cancer treatment.
  • HY-104042
    Vorasidenib Inhibitor 99.38%
    Vorasidenib is a pan isocitrate dehydrogenase (IDH) inhibitor.
  • HY-15734
    AGI-6780 Inhibitor 98.55%
    AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2WT with IC50 of 190±8.1 nM.
  • HY-19540
    GSK864 Inhibitor 99.36%
    GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC50 values of 8.8, 15.2 and 16.6 nM.
  • HY-104036
    IDH-305 Inhibitor 98.01%
    IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH).
  • HY-13972
    Mutant IDH1 inhibitor Inhibitor 98.03%
    Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
  • HY-18767A
    (R,S)-Ivosidenib Inhibitor 99.40%
    (R,S)-Ivosidenib is a inhibitor of Isocitrate Dehydrogenase (IDH1).
  • HY-100020
    BAY-1436032 Inhibitor 98.94%
    BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
  • HY-18717
    Mutant IDH1-IN-2 Inhibitor
    Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
  • HY-12475
    Mutant IDH1-IN-1 Inhibitor
    Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
  • HY-18690A
    Enasidenib mesylate Inhibitor 99.25%
    Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.